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Abstract
Objectives Although botulinum neurotoxin type A
(BoNT/A) intradetrusor injections are a recommended ther-
apy for neurogenic detrusor overactivity (NDO), refractory
to antimuscarinic drugs, a standardisation of injection tech-
nique is missing. Furthermore, some basic questions are
still unanswered, as where the toxin solution exactly
spreads after injection. Therefore, we investigated the
distribution of the toxin solution after injection into the
bladder wall, using magnet resonance imaging (MRI).
Methods Six patients with NDO were recruited. Three of
six patients received 300 U of BoNT/A + contrast agent
distributed over 30 injection sites (group 1). The other three
patients received 300 U of BoNT/A + contrast agent dis-
tributed over 10 injection sites (group 2). Immediately after
injection, MRI of the pelvis was performed. The volume of
the detrusor and the total volume of contrast medium inside
and outside the bladder wall were calculated.
Results In all patients, a small volume (mean 17.6%) was
found at the lateral aspects of the bladder dome in the extra-
peritoneal fat tissue, whereas 82.4% of the injected volume
reached the target area (detrusor).
In both groups there was a similar distribution of the
contrast medium in the target area. A mean of 33.3 and
25.3% of the total detrusor volume was covered in group 1
and 2, respectively. Six weeks after injection, Wve of six
patients were continent and showed no detrusor overactivity
in the urodynamic follow-up. No systemic side eVects were
observed.
Conclusions Our results provide morphological argu-
ments that the currently used injection techniques are
appropriate and safe.
Keywords Botulinum neurotoxin type A · 
Neurogenic detrusor overactivity · Magnetic resonance 
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Introduction
Botulinum neurotoxin type A (BoNT/A) injections into the
detrusor muscle are a recommended therapy for neurogenic
detrusor overactivity (NDO), when antimuscarinic drug
therapy failed or is not tolerated [1–4]. BoNT/A injections
have been successfully used to treat NDO worldwide and
further indications and therapy options are currently
explored [5–8]. The toxin is injected into the detrusor mus-
cle via a cystoscopic approach, either Xexible or rigid. The
injection needle, which can be of diVerent length and diam-
eter, is stabbed into the bladder wall, followed by the injec-
tion of the toxin and the retraction of the needle. This is
usually performed at multiple sites of the bladder wall,
depending on the technique and amount of toxin, chosen
for therapy [3, 9]. Target structure of the toxin is the detru-
sor muscle, as its main mechanism of action is at the neuro-
muscular junction [10, 11]. However, detrusor thickness is
variable and depends on several factors such as gender, age,
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or obstruction [12, 13]. Although injection is performed
under cystoscopic guidance, injection depth can only be
estimated by the surgeon. Therefore, it remains diYcult to
estimate exactly in which layer the toxin is injected and
where it spreads out. The sole visual control could be a
bulging of the bladder wall after injection. If a big transpar-
ent bleb forms, the injection was probably superWcial in the
muscosa, if a slight bulging of bladder wall tissue can be
observed the injection was probably in the detrusor layer.
But very often, no bulging can be observed at all and it
remains a very insecure sign of a correct injection.
Although the injection of BoNT/A is frequently used to
treat NDO, no standardisation of technique exists [9, 14,
15]. There are repeatedly reports of treatment failures, even
in those patients, who formerly showed an excellent treat-
ment response to BoNT/A [16–18]. Not all treatment fail-
ures can be explained properly and one reason for this
might be a variation in the amount of toxin that reaches its
target area.
Therefore, it was our purpose to investigate for the Wrst
time, the distribution of the toxin solution after injection
into the bladder wall, using magnet resonance imaging
(MRI). Since we previously investigated the use of two
diVerent injection schemes (10 vs. 30 injection sites), which
showed similar clinical results [14], we were also interested
to observe the morphological outcome of both injection
schemes.
Due to our long term experience with the use of BoNT/A
in the treatment of NDO and our favourable results in those
years [19, 20], we expected most of the toxin to be found in
the detrusor. Nevertheless we also expected some toxin out-
side the detrusor, as perforation can not be completely
excluded using the cystoscopic approach. As a secondary
outcome measure we evaluated the urodynamical data
before and after BoNT/A injection to be able to correlate
the clinical outcome with the morphological evaluation of
the toxin distribution.
Materials and methods
After approval of the local ethics committee, a patient sam-
ple was recruited in the neurourological out-patient clinic
of the spinal cord injury centre at the Balgrist University
Hospital.
Inclusion criteria were: urodynamically proven NDO,
failure to treatment with antimuscarinic drugs, minimum
age of 18.
Exclusion criteria: allergy to BoNT/A or to MRI contrast
agents, any existing malignancy in the bladder or urethra,
urinary tract infection, pregnancy, breastfeeding, incapabil-
ity or unwillingness to perform intermittend selfcatheterisa-
tion, coagulation disorders or intake of anticoagulant drugs,
impaired renal function, myasthenia gravis, pacemaker,
Lambert–Eaton syndrome, medication with aminoglyco-
sides (or other drugs with impact upon neuromuscular
transmission), any ferromagnetic metal implants or com-
pounds in or at the body.
Prior to inclusion, all patients were informed about the
character of the study, both verbally and in writing and
each patient had to provide written informed consent.
Pre-treatment evaluation consisted in physical examina-
tion, medical history, cystomanometry, blood chemistry,
urine sediment and culture. Infections were treated accord-
ing to germ resistance before examination or injection and
all patients received antibiotic prophylaxis for 3 days, start-
ing 1 day before injection and ending 1 day after injection.
Local anaesthesia using electromotive drug administra-
tion of 2% lidocain was applied in patient 2 because of pre-
served bladder sensibility due to an incomplete spinal cord
lesion (Table 1) [21].
The BoNT/A injections were performed at the bladder
base and dome in a standardised manner by the same sur-
geon in all patients, using a rigid cystoscope (19 or 22 Fr)
and a 22 G (=0.7 mm) needle with a length of 8 mm. Not
the full needle length was inserted into the bladder wall
during injection. Instead, the needle was retracted up to half
its length, depending on the injection angle. The used
BoNT/A compound in this study was BOTOX® (Allergan
AG, Lachen, Switzerland).
The Wrst group (group 1) of patients received 300 U of
BOTOX®, distributed over 30 injection sites each 1 ml
BoNT/A solution [3]. A second group (group 2) received
300 U of BOTOX®, distributed over ten injection sites each
1 ml BoNT/A solution [14]. For group 1, 300 U of
BOTOX® were diluted in 27 ml 0.9% saline + 3 ml gadop-
entate. For group 2, 300 U of BOTOX® were diluted in
9 ml 0.9% saline + 1 ml gadopentate. The paramagnetic
MRI contrast agent gadopentate (Magnevist®, Schering
AG, Berlin, Germany) was mixed into the BoNT/A solu-
tions to detect the distribution of the injections in the fol-
lowing MR-scans, which were performed in a 1.5 T Avanto
Siemens Magnetom. Prior to scanning, the bladder of all
patients was emptied and Wlled with 200 ml 0.9% saline to
achieve a standardised Wlling during MR scanning.
A T1 fast low angle shot (FLASH) 3D with fat satura-
tion was used in the MR evaluation including the following
speciWcations: TR: 4 ms, TE: 1.7 ms, Xipangle: 12°, matrix:
256 £ 256, FOV: 200 mm, slice thickness: 2.9 mm, NEX
(Acquisitions): 2.
Using the freehand tool of the MR-software, the follow-
ing regions of interest (ROIs) were selected: (1) the area of
contrast agent within the detrusor muscle, (2) the area of
contrast agent outside the detrusor and (3) the whole detrusor
itself. Once a ROI was deWned, the software automatically123
World J Urol (2009) 27:397–403 399calculated the area in square millimetres. The 3D acquisi-
tion technique enabled the generation of volume data by
multiplying the previously measured ROIs of each slice
with the slice thickness. The distribution of gadopentate
after injection was calculated and evaluated by two diVer-
ent radiologists who were blinded to the injection protocol.
An urodynamic control visit was scheduled for each patient
3 months after injection and the urodynamic outcome mea-
sures were compared with those before BoNT/A injection.
Results
Six patients with spinal cord injury and subsequent NDO
could be included (Table 1). All injections could be per-
formed without any clinically evident adverse events and
none of the patients felt discomfort or pain. Only in patient
6, the injection procedure itself was diYcult because of an
increased spasticity of the lower limb. No systemic side
eVects were observed in any patient directly after the injec-
tion or during follow-up. Bleeding from the injection sites
was minimal and stopped shortly after retracting the needle.
The average delay between the end of the BoNT/A injec-
tion and the start of the Wrst MR-sequence was 17.5 min,
ranging from 10 to 32 min. Mean examination time in the
MR-scanner was 25 min, ranging from 17 to 42 min.
In none of the patients, contrast agent could be detected
intraperitoneal, which would be highly suspicious for a
penetration into the peritoneum. Furthermore, no contrast
agent was found in other organs like the rectum or pelvic
muscles. In all six patients, fractions of the contrast agent
could be detected outside the bladder wall, located in the
perivesical fat, mainly at the lateral aspects of the bladder
dome either on one or both sides. In one patient contrast
agent was also found beyond the bladder base, in another
patient beyond the middle part of the bladder dome. The
average spreading distance of contrast agent from the outer
margin of the detrusor was 16 mm.
The mean total detrusor volume of all subjects was
156.4 cm3. The mean contrast enhanced detrusor volume of
all subjects was 46.3 cm3 (29.3% of the mean total detrusor
volume). The mean amount of contrast enhanced volume
outside the detrusor was 8.7 cm3 (17.6% of the mean total
contrast enhanced volume). Accordingly, 82.4% of contrast
agent was found within the detrusor (Table 1).
In group 1, the mean total detrusor volume was 199 cm3.
The mean volume of detrusor, found to be contrast
enhanced, was 62.8 cm3 (33.3% of the mean total detrusor
volume in group 1). The mean amount of contrast enhanced
volume outside the detrusor was 10.7 cm3 (14.3% of the
mean total contrast enhanced volume). Accordingly, 85.7%
of contrast agent was found within the detrusor (Table 1).
In group 2, the mean total detrusor volume was
113.7 cm3. The mean volume of detrusor, found to be con-
trast enhanced, was 29.9 cm3 (25.3% of the mean total
detrusor volume in group 2). The mean amount of contrast
enhanced volume outside the detrusor was 6.6 cm3 (20.8%
of the mean total contrast enhanced volume). Accordingly,
79.2% of contrast agent was found within the detrusor
(Table 1).
In Wve of six patients, the BoNT/A injections showed
to be eVective. Before treatment, all six patients had NDO
in their urodynamic examination. The average volume at
which the Wrst detrusor overactivity (DO) could be
Table 1 Patients characteris-
tics, urodynamic data before and 
after treatment, and the data of 
the magnet resonance imaging 
analysis of all six patients
P 1 P 3 P 5 P2 P 4 P 6
Age 34 34 41 82 67 18
Sex Male Male Male Female Male Female
Level of SCI Th11 Th6 Th6 Th7 Th10 Th10
ASIA classiWcation A A A C A A
Max. bladder capacity before treatment (ml) 217 300 222 217 200 249
Max. detrusor pressure before treatment (cmH2O) 69 46 41 37 48 27
Incontinence/urine leak Yes Yes Yes Yes Yes Yes
Units of Botox® 300 300 300 300 300 300
No. injection sites 30 30 30 10 10 10
Max. bladder capacity after treatment (ml) 381 500 500 186 500 440
Max. detrusor pressure after treatment (cmH2O) 57 10 8 36 11 10
Incontinence/urine leak No No No Yes No No
Volume detrusor (cm3) 217.16 253.95 126.02 64.55 198.3 78.27
Volume contrast medium (total) (cm3) 101.53 61.2 57.74 14.51 56.57 38.53
Volume contrast medium inside detrusor (cm3) 85.6 52.97 49.76 11.52 54.08 24.11
Volume contrast medium outside detrusor (cm3) 15.93 8.23 7.98 2.99 2.49 14.42
P patient, SCI spinal cord injury, 
ASIA American Spinal Injury 
Association, Th thoracic spine123
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was on average 44.7 cmH2O. Five of six patients had urinary
incontinence (Table 1).
After the BoNT/A injections, four of six patients had no
DO up to 500 ml and were continent. In patient 1 bladder
capacity at least increased from 217 to 381 ml and the max-
imum detrusor pressure decreased from 69 to 57 cmH2O
(Table 1). Patient 2 showed no improvement in the follow-
up cystometry, although he reported improvement. This
patient had the lowest percentage of detrusor volume cov-
ered by the contrast agent (Table 1).
Due to the spastic limb contractions in patient 6, shifts in
the penetration depth of the needle might have incidentally
occurred. When analysing this patient’s data we found that
nearly 40% of the applied contrast agent was located
beyond the detrusor (Table 1).
All patients would agree to a second injection, when the
eVect of the last injection fades.
Discussion
The aim of this study was to investigate the distribution of
the BoNT/A solution, after injection into the bladder wall.
Our data show, that using the previously described and
most widely used injection technique with 30 or 10 injec-
tion sites [3, 14], most of the applied volume spreads inside
the detrusor. Only small amounts were found outside the
detrusor, almost exclusively in the fat tissue at the lateral
aspects of the bladder dome.
That 82.4% (average of all 6 subjects) of the injected
BoNT/A-gadopentate solution were detected inside the
detrusor, met our expectations. In regard with the clinical
improvement of the patients, these results show that the
used techniques are accurate and eYcient.
Due to the fact, that contrast agent could be detected out-
side the detrusor, it has to be assumed that the injection
needle perforated the detrusor during some of the injec-
tions. This is probably not uncommon following detrusor
injections via a cystoscopic approach, as the surgeon can
only estimate the relation of needle length to detrusor thick-
ness. These two factors, e.g. needle length and detrusor
thickness, are most crucial in regard to injection depth. One
can now assume that the surgeon could choose the needle
length according to the detrusor thickness, which can be
measured using ultrasound at a deWned Wlling level [12].
This measurement, however, might not be very reliable
during cystoscopic BoNT/A injection, as Wlling volumes
and therefore detrusor thickness is likely to change during
cystoscopy due to diuresis and more likely due to the regu-
lar use of Xushing and draining of saline. Additionally,
detrusor thickness might not be the same throughout the
bladder, although investigated by Kutzmic [22], who found
per individual the same detrusor thickness in all parts of the
bladder wall. This is probably true for healthy subjects but
might be completely diVerent for patients with NDO.
Perforation might not be the only mechanism contribut-
ing to the extravesical amount of contrast medium. A diVu-
sion of the BoNT/A-gadopentate solution outside the
bladder can not be excluded in principle. Although one
would expect a more homogeneous and broader extravesi-
cal accumulation of the contrast medium and not only at
certain areas as shown in Fig. 1.
The amount of the injected BoNT/A-gadopentate solu-
tion found outside of the bladder wall in the present study
seemed to be low enough, not to cause any systemic side
eVects or to compromise the eVect of the toxin on the blad-
der. Most of the intradetrusor contrast agent was found in
the bladder base and dome, since this are the locations we
injected. When descriptively comparing the two diVerent
treatment modalities (30 vs. 10 injection sites) there was a
similar amount of contrast agent found in the target area
(85.7 vs. 79.2%) and a similar percentual coverage of detru-
sor volume with the contrast agent (33.3 vs. 25.3%).
Although both groups can not be compared statistically due
to the small sample size, this Wnding can still be seen in
agreement with the study from Karsenty et al. [14], who
found no diVerence in clinical eYcacy and safety using 10
compared to 30 injection sites with the same amount of
BoNT/A.
Fig. 1 An exemplary coronal 
slice of the magnet resonance 
imaging of the lower pelvis, 
showing the urinary bladder in 
the middle of the image. The 
contrast agent, appearing in 
white, can be found for the most 
part within the detrusor (a) and 
to some extent outside the detru-
sor in the perivesical fat tissue 
(b) (the areas were encircled in 
red for better visibility)123
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tissue should be covered to gain the best dosage/eVect ratio
of BoNT/A. One would assume that a distribution of
BoNT/A covering most of the detrusor body might cause
the greatest eVect. In the present study an average of only
about 30% (mean of all patients) of detrusor muscle was
covered with contrast agent. Nevertheless, a suYcient eVect
of the BoNT/A treatment could be observed, which is well
comparable with the success rates reported in former stud-
ies [6, 7]. Therefore, it might not be necessary to cover the
whole detrusor with BoNT/A, to achieve good clinical
results.
An exact explanation why 30% detrusor coverage with
BoNT/A are suYcient enough to produce the reported clin-
ically signiWcant improvements can not be given with this
study. A possible reason eventually underlying these results
might be areas of detrusor tissue, which are more important
for detrusor contraction and increase of local reXex activity
than other areas after spinal cord injury [23]. Treatment of
those areas with BoNT/A might be suYcient enough to
reduce detrusor contractions in NDO patients, regardless of
the total amount of detrusor area covered. Experimental
studies in neonate and spinal cord injured rats showed that
spontaneous contractile activity originated in the urothe-
lium-suburothelium near the bladder dome [23, 24]. This
spontaneous activity, unlike activity in normal adult rat
bladders, is highly organised, i.e. starting at the dome, fol-
lowed by the bladder body further contracting towards the
bladder outlet. These organised contractions resulted in
high amplitudes (10–20 cmH2O). Increased expression of
gap junctions seems to play a role in this coordinated con-
traction in neonate and spinal cord injury bladders, which
gives the impression, that the bladder works partially like a
“functional syncytium” [24].
In addition, BoNT/A is not only inhibiting the eVerent
pathway by preventing neuronal acetylcholine release but
also modulating the aVerent pathway due to its eVect on
receptors and neurotransmitter release from the urothelium
and suburothelium, which probably adds to the eYcacy of
the toxin in the treatment of DO [25–27].
Disruption of such organised synergic contractions and
of the urothelial and suburothelial para- and autocrine
signalling by an area of 30% of the total detrusor, due to
intradetrusor injection of BoNT/A at and around the
bladder dome might not completely abolish detrusor con-
tractions (Table 1), but prevent complete and/or large
amplitude contractions arising from the bladder dome. This
is probably suYcient enough to prevent incontinence and
cause satisfying clinical results. Interestingly, two studies
mainly using injections at the bladder base reported a sig-
niWcant lower rate of complete continent patients with
NDO compared to other studies injecting BoNT/A in base
and dome [7, 28, 29].
Further investigations are necessary to evaluate the
degree of detrusor coverage with BoNT/A compared with
the clinical outcome. Presumably there is an optimal ratio
between the amount and the degree of distribution of
BoNT/A inside the detrusor and the clinical outcome,
which is worth to be discovered. Using MRI in conjunction
with contrast enhanced BoNT/A solution, might be a very
useful tool to perform this investigation.
There are, however, limitations of the used investiga-
tion method. First limitation is that during the injection
procedure there might be some volume leaking out of the
injection site into the bladder lumen. We consider this vol-
ume as extremely low, as the needle diameter is very small
and most injection sites will clot shortly after removing the
needle, which is in accordance with the experience of
Schulte–Baukloh, who investigated toxin back Xow from
the injection site using a dye. He found, although not spe-
ciWcally quantiWed, that none to extremely little dye/toxin
is Xowing back from the injection sites [30]. QuantiWca-
tion of a dye (e.g. methylene blue) in the bladder irrigation
Xuid requires at least a photometric device, which was not
readily available in our clinic. The group around Helmut
Madersbacher and Gustav Kiss from the University of
Innsbruck very recently performed such a photometric
evaluation and found out that only 1.96–19.2 U (median
5.5 U) of 170–400 U BoNT/A are lost due to back Xow
after injection (personal communication, annual meeting
of the German Urological Association in Stuttgart, 24–27
Sep 2008).
Second limitation might be measurement errors.
Although most borders could be clearly distinguished,
extravesical Xuid may not have perfectly smooth borders.
Manual determination of the region of interest introduces
an additional small error. These errors were minimised by
having two senior radiologists experienced in quantitative
assessments of MR images performing the evaluations in
consensus. The remaining error is small in comparison to
the measured volumes.
Third limitation is the number of six patients, which is
too small to receive data for reliable statistics, but besides
monetary constraints (expensive MRI-examinations) the
focus of this study was to demonstrate morphological
aspects of the injection technique for the Wrst time. The
used MRI technique is well suited to demonstrate the mor-
phologic situation after injecting the detrusor, but a short
delay between injection and obtaining the pictures is man-
datory because of fast diVusion and venous backXow of the
contrast agent.
At least, it has to be considered that we can not demon-
strate the localisation of the BoNT/A itself, but only the
localisation of the contrast agent. Although BoNT/A is not
residing just at the injection site [31], it probably diVuses
much slower and less far as gadopentate, due to the higher123
402 World J Urol (2009) 27:397–403molecular weight of 150 kDa compared to the 835 Da of
gadopentate. In our study (with a mean delay of 17.5 min
after injection) renal excretion of contrast agent could
already be seen in all patients.
Conclusion
Using the previously described injection techniques, a
mean of 82.4% of the injected BoNT/A-gadopentate solu-
tion can be found within the detrusor. However, a perfora-
tion with the needle tip and injection into the perivesical
tissue could not be prevented. Treatment with 10 or 30
injection sites seem similar regarding the distribution of
contrast agent in or outside the detrusor. In consideration of
the clinical improvements of the patients, our results pro-
vide further arguments that the currently used injection
techniques are appropriate and safe. Further studies are nec-
essary to explore the optimal ratio between the amount and
the degree of dissemination of BoNT/A inside the detrusor
and the clinical outcome.
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